title: Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score.
abstract: OBJECTIVE
  To date all prediction models for patients with renal cell carcinoma have estimated outcome in static fashion starting from the date of surgery only. We created a dynamic outcome prediction model for continual surveillance that accounts for the disease-free interval following surgery.
  
  
  METHODS
  We identified 1,560 patients treated with radical nephrectomy for pM0 clear cell renal cell carcinoma between 1970 and 1999. The previously published stage, size, grade and necrosis score was used to stratify patients according to the risk of death from renal cell carcinoma. Cancer specific survival rates were calculated using the Kaplan-Meier method at surgery and at various disease-free intervals following surgery.
  
  
  RESULTS
  At last followup 461 of the 1,560 patients had died of renal cell carcinoma at a median of 3.1 years following surgery. Median followup in patients still alive was 11.2 years. Patient outcome improved as the disease-free interval following surgery increased. For example, patients with a stage, size, grade and necrosis score of 5 had an estimated 5-year cancer specific survival rate of 69.6% at surgery. However, those who survived without disease for 1, 2 and 3 years following surgery had adjusted estimated 5-year cancer specific survival rates of 81.9%, 91.9% and 93.2%, respectively. Patients with a stage, size, grade and necrosis score of 7 had a 5-year cancer specific survival rate of 44.9% at surgery, which increased to 63.3%, 71.0% and 72.8% after 1 to 3 years of disease-free followup, respectively.
  
  
  CONCLUSIONS
  Within each stage, size, grade and necrosis score cancer specific survival rates increase as the disease-free interval following surgery increases. We present a dynamic outcome prediction model that allows clinicians to continually adjust surveillance as the disease-free interval increases.
authors.affiliation: Department of Urology, Health Sciences Research, Mayo Medical School, Mayo Clinic, Rochester, Minnesota, USA.
authors.forename: R Houston
authors.initials: RH
authors.lastname: Thompson
authors.forename: Bradley C
authors.initials: BC
authors.lastname: Leibovich
authors.forename: Christine M
authors.initials: CM
authors.lastname: Lohse
authors.forename: John C
authors.initials: JC
authors.lastname: Cheville
authors.forename: Horst
authors.initials: H
authors.lastname: Zincke
authors.forename: Michael L
authors.initials: ML
authors.lastname: Blute
authors.forename: Igor
authors.initials: I
authors.lastname: Frank
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002292:Carcinoma, Renal Cell / Q000601:surgery*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D015233:Models, Statistical; D009392:Nephrectomy / Q000379:methods; D011379:Prognosis